

# Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

NCT04165486

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Ionis Pharmaceuticals, Inc.
<b>Enrollment</b>	40 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Screening single-photon emission computed tomography (SPECT) with DaTscan™ (ioflupane I123 injection) results demonstrating loss (whether symmetric or asymmetric) of dopamine nerve terminals in the striatum consistent with neurodegenerative parkinsonism, as assessed with qualitative, visual read.
- Diagnosed with probable or possible MSA, either parkinsonian-type (MSA-P) or cerebellar-type (MSA-C).
- Must be able to walk unassisted for at least 10 meters (approximately 30 feet)

### Exclusion (2)

- Presence of cognitive dysfunction (defined as Montreal Cognitive Assessment (MoCA) score  $\leq 25$ )
- Family history of ataxia or parkinsonism and known genetic cause of ataxia or parkinsonism.

## Locations (14 total)

---

Medizinische Universität Innsbruck, Innsbruck, Austria  
CHU de Lyon - Hospices Civils de Lyon-Hôpital Pierre Wertheimer, Neurologique HCL, Lyon, France  
Groupe Hospitalier Pitie-Salpetriere, Paris, France  
... and 11 more locations